>>> US Gapping down

Gapping down
In reaction to earnings/guidance:
  • GRPN -34.4% (also Co-Founder Eric Lefkofsky to resign; to raise $100 mln to strengthen liquidity), PLUG -33.2%, TWOU -28.2%, TTD -24%, TMCI -19.4%, VUZI -16.7%, WEST -15.6%, BW -15.2% (also announces business realignment plan; considering strategic alternatives related to non-strategic assets), U -14.9% (also files for $1.0 bln 2.0% Convertible Senior Notes), MODN -12.3%, GDOT -11.4%, ILMN -11.2%, EVBG -7.1%, ADPT -5.6%, NWSA -5.6%, VYX -5%, PAR -4.9%, ONTO -4.8%, WYNN -4.7%, HE -4.6% (also to delay its 10-Q citing potential lawsuits), CLNE -4.5%, FLO -3.4%, BBDC -3.1%, CPRI -3%, CLFD -2.4% (also increases share repurchase program), AQN -1.6%, RBA -1.4%, LAW -1.2%
Other news:
  • TKO -6.8% (prices secondary offering of 8.4 mln shares of common stock at $79.80 per share) BRNS -5.8% (ABUS and BRNS announce a late breaking poster presentation)
  • NBIX -5.5% (Phase 2 study of NBI-1065846 in patients with anhedonia failed to meet primary endpoint)
  • IRDM -4.6% (QCOM elects to terminate agreements)
  • OABI -3.7% (Highlights OmnidAb Launch and its Expanding Drug Discovery Platform at co's Research & Technology Virtual Event)
  • LMND -3.6% (files mixed shelf securities offering; also files for offering by selling shareholder)
  • PIII -3.6% (files $250 mln mixed shelf securities offering)
  • GOL -3% (reports October metrics)
  • SKYW -2.1% (stock offering by selling shareholders)
  • AZUL -1.8% (reports October traffic increased 13.7% yr/yr)
  • XENE -1.3% (NBIX partner Phase 2 study of NBI-1065846 in patients with anhedonia failed to meet primary endpoint)
  • CPK -1% (prices offering of 3859649 shares of its common stock at an offering price of $85.50 per share)

Analyst comments:
  • COMM -4.5% (downgraded to Neutral from Buy at BofA Securities)
  • WWW -2.8% ( downgraded to Sell from Hold at Williams Trading)
  • MPW -2.2% (downgraded to Hold from Buy at Stifel)
  • LUV -1.2% (downgraded to Underperform from Neutral at Exane BNP Paribas)
  • AAL -0.5% (downgraded to Neutral from Outperform at Exane BNP Paribas)
  • JBLU -0.5% (downgraded to Underperform from Neutral at Exane BNP Paribas)